GlassScriptPhysician profile
Stephanie E Smith-Phillips
NPI 1518922509
$11,279.60
in general payments reported to CMS, 2019-2025
45 companies · $2,185 in 2025
The $2,185 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,384 · 2020: $664 · 2021: $1,415 · 2022: $1,371 · 2023: $2,000 · 2024: $2,261 · 2025: $2,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,347 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,346.59 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $978.61 | 2019-2025 | |
| Janssen Biotech, INC. | $879.44 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $661.77 | 2019-2025 | Rinvoq, Botox, Skyrizi |
| Arcutis Biotherapeutics, INC. | $630.29 | 2023-2025 | Zoryve |
| Genzyme Corporation | $608.01 | 2021-2025 | |
| Almirall LLC | $581.48 | 2019-2025 | Klisyri, Seysara |
| Sun Pharmaceutical Industries INC. | $544.13 | 2019-2025 | Ilumya, Winlevi |
| Leo Pharma INC. | $483.87 | 2019-2025 | Adbry, Anzupgo |
| Amgen INC. | $465.95 | 2019-2025 | Otezla, Enbrel, Otezla |
| Mayne Pharma Commercial LLC | $456.30 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $440.07 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $398.12 | 2019-2025 | |
| Galderma Laboratories, L.P. | $391.81 | 2019-2025 | Nemluvio |
| Incyte Corporation | $345.46 | 2021-2025 | Opzelura |
| Allergan, INC. | $333.71 | 2021-2022 |
Show all 44 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Smith-Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.